Intellia’s data, IRA’s orphan impact, CFIUS order

A year after it reported its first clinical data showing CRISPR-based gene editing may live up to its promise,  Intellia Therapeutics Inc. (NASDAQ:NTLA) has provided evidence for the second time that its platform can knock down a clinically relevant target in the liver, and revealed the first data showing it can deliver clinical benefit. On the latest BioCentury This Week podcast, BioCentury Executive Editor Lauren Martz and Editor in Chief Simone Fishburn discuss the hereditary angioedema data for NTLA-2002.

Washington Editor Steve Usdin explains why the Inflation Reduction Act could have an outsized effect on the development of orphan drugs and how an Executive Order related to the Committee on Foreign Investment in the United States (CFIUS) signed by President Joe Biden singles out biotech and biomanufacturing for intensified foreign investment scrutiny.  

This week’s podcast is sponsored by the BioCentury-BayHelix East-West Summit 2022, which takes place in the San Francisco Bay Area Nov. 14-16. For information on how to sponsor BioCentury This Week and/or The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.